Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Delayed Data from NSDQ)
$6.80 USD
+0.04 (0.59%)
Updated Aug 7, 2025 03:59 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BDRX 6.80 +0.04(0.59%)
Will BDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock
BDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade
Other News for BDRX
ADR Ratio Change Effective | BDRX Stock News
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover ...
Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance